CELF2

Across TCGA pan-cancer cohorts, CELF2 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of CELF2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where CELF2 RNA is repressed in tumor relative to normal tissue. In most cancer types CELF2 is over-expressed in tumor, although a few such as BLCA and LUAD show the opposite, repressed pattern.

BLCA, LUAD, and KIRC are the cancer types where CELF2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CELF2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	III,IV	−2.914	<.001	11	view →
LUAD	Female	II,III,IV	−1.437	<.001	10	view →
KIRC	Male	All	+0.973	<.001	10	view →
LUSC	Male	II,III,IV	−2.505	<.001	9	view →
UCEC	All	All	−2.405	<.001	6	view →
BRCA	All	III,IV	−1.818	<.001	6	view →
KICH	Male	All	+1.020	.002	4	view →
THCA	Female	All	−0.622	.001	4	view →
COAD	All	All	−0.416	.008	4	view →
KIRP	All	All	+0.693	.003	3	view →
PAAD	All	All	−2.044	.048	2	view →
STAD	All	All	−0.909	.011	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

CELF2–BLCA

Open the BLCA breakdown →